Filing Flows › Celldex Therapeutics (CLDX) › R&D spending
Celldex Therapeutics (CLDX) R&D spending by quarter
Celldex Therapeutics' R&D spending was $67.5M in Q2 2026 (second quarter 2026), -7% from Q1 2026. Over the last 6 quarters it ranged from $46.9M (Q4 2024) to $75.3M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $67.5M | -7% | +25% |
| Q1 2026 | $73.0M | -3% | +39% |
| Q4 2025 | $75.3M | +39% | +60% |
| Q2 2025 | $54.2M | +3% | — |
| Q1 2025 | $52.6M | +12% | — |
| Q4 2024 | $46.9M | — | — |
Q2 2026 at a glance
Celldex Therapeutics, Q2 2026: revenue $22K (-97% year over year), net loss $73.5M, operating cash flow −$57.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Celldex Therapeutics' R&D spending?
Celldex Therapeutics' R&D spending was $67.5M in Q2 2026 (second quarter 2026), -7% from Q1 2026.
How has Celldex Therapeutics' R&D spending changed?
Over the last 6 quarters it ranged from $46.9M (Q4 2024) to $75.3M (Q4 2025).